New drug trial targets Tough-to-Treat prostate cancer
NCT ID NCT07493512
Summary
This early-stage study is testing the safety of an experimental drug called xaluritamig in men with advanced prostate cancer that has spread and no longer responds to standard hormone-blocking treatments. The trial will enroll about 40 participants to monitor for side effects and see how the drug behaves in the body. Researchers will also check if the treatment helps slow the cancer's growth or reduce a key cancer marker called PSA.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.